Madrigal Pharmaceuticals Presents New Data From The Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects Of Resmetirom On Noninvasive Measures Of Liver Health
Portfolio Pulse from Benzinga Newsdesk
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has presented new data from the Phase 3 MAESTRO-NASH trial, demonstrating broad treatment effects of resmetirom on noninvasive measures of liver health. Over 70% of patients treated with resmetirom 100 mg experienced a ≥30% reduction in MRI-PDFF, which predicted treatment response on biopsy. The FDA granted Priority Review for the new drug application (NDA) seeking accelerated approval of resmetirom for the treatment of NASH with liver fibrosis in September 2023.
November 10, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Madrigal Pharmaceuticals' new data from the Phase 3 MAESTRO-NASH trial shows promising results for resmetirom, potentially leading to accelerated FDA approval.
The positive results from the Phase 3 MAESTRO-NASH trial are likely to boost investor confidence in Madrigal Pharmaceuticals. The FDA's Priority Review for resmetirom could lead to accelerated approval, which would be a significant milestone for the company.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100